Enrollment has commenced for the dosing of PAS-004, a promising investigational drug, in three patients diagnosed with advanced solid tumors driven by the MAPK pathway. This marks a significant step forward in the ongoing phase 1 clinical trial initiated by Pasithea Therapeutics.
Rapid Enrollment Progress
Dr. Tiago Reis Marques, the chief executive officer of Pasithea, expressed enthusiasm over the swift recruitment and dosing of the initial participants. The trial aims to complete enrollment for all patients by the end of 2025, showcasing the commitment to expedite research in this critical area.
Study Design and Patient Eligibility
This phase 1 trial is designed as a multicenter, open-label, dose-escalation study. It focuses on evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with tumors characterized by specific mutations such as RAS, NF1, or RAF. Furthermore, participants must have experienced disease progression following BRAF/MEK inhibition to qualify for the study.
Patients enrolled in the trial will undergo regular monitoring through doctor visits and health assessments. Each participant will take a single oral dose of PAS-004, followed by a one-week observation period before transitioning to daily doses during 28-day cycles. The treatment could continue for up to two years, contingent on the patient’s health status and willingness to remain in the study.
Trial Locations
The trial is being conducted at seven sites across the United States, including cities in Texas and Virginia. Additionally, the study extends its reach to Bulgaria and Romania, demonstrating a robust international collaboration in cancer research.
Safety and Tolerability of PAS-004
Early data from prior cohorts indicate that PAS-004 has a favorable safety profile. In the initial dosing phases, six patients received either 2 milligrams or 4 milligrams of the drug. There were no reports of serious adverse effects or treatment interruptions, underscoring the drug’s tolerability. Notably, patients did not experience common side effects often associated with oncology treatments, such as those affecting the skin, gastrointestinal system, or eyesight.
Unique Pharmacokinetic Profile
Dr. Marques highlighted the distinct pharmacokinetic properties of PAS-004, which distinguishes it from traditional MEK inhibitors. With a half-life of approximately 70 hours, PAS-004 is designed to maintain a steady therapeutic effect while minimizing peak plasma toxicities. This characteristic is particularly significant for patients with NF1-mutated cancers where existing treatments often have much shorter half-lives.
Sequential Dose Escalation
The trial employs a sequential dose-escalation approach, with doses ranging from 2 milligrams up to 45 milligrams. This systematic increase allows researchers to monitor the drug’s safety and efficacy clearly while determining the optimal therapeutic dose.
Primary endpoints of the study include identifying dose-limiting toxicities and evaluating hematology and clinical chemistry parameters. These metrics will provide crucial insights into the clinical usefulness of PAS-004.
Conclusion
The initiation of PAS-004 dosing in patients with MAPK-driven tumors represents a promising development in cancer treatment. With its unique pharmacokinetic advantages and a focus on patient safety, PAS-004 could pave the way for more effective therapies in the fight against advanced solid tumors. As the trial progresses, it holds the potential to offer hope to many patients facing limited treatment options.
- PAS-004 dosing has begun for MAPK-driven tumors.
- The trial aims to complete enrollment by the end of 2025.
- Preliminary data suggest a favorable safety profile for PAS-004.
- The drug features a long half-life, minimizing peak plasma toxicities.
- The study includes multiple locations across the U.S. and Europe.
Read more → www.curetoday.com